Sign in

HKPD on Nasdaq

Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd is a wholesale-drugs company in the Cayman Islands, listed on Nasdaq (HKPD).1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with DataMeds AI, Inc., Cosmos Health Inc. or Stemtech Corp, or pick any stock.

  • TickerHKPD on Nasdaq1
  • IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries1
  • HeadquartersE91
  • Incorporated inCayman Islands2
  • Business addressRoom B1, 5/F. Well Town Ind. Building, 13 Ko Fai Road, Yau Tong, Kowloon2
  • Filer categoryNon-accelerated filer, Emerging growth company2

See how the biggest companies compare on our leaderboards

2023, it had an authorized share capital of $50,000 divided into 50,000,000 ordinary shares of a single class, par value $0.001 per share.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

11.9%Gross margin4
-11.2%Operating margin4
-0.1%Net margin4
21.7%Revenue growth, 20254
-0.5%Return on equity4
0.30×Debt to equity4
$499.3KFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Supply Chain Services brought in 56% of the revenue Cellyan Biotechnology Co., Ltd broke down this way in fiscal 2026.

  1. Supply Chain Services$7.6M556%down 39% from 2025
  2. Procurement And Distribution$5.9M544%down 22% from 2025
  3. Consignment Sales And Other Revenue$4.2K50%down 99% from 2025
Products and services by year
Products and services202420252026
Supply Chain Services$10.1M$12.5M$7.6M
Procurement And Distribution$6.2M$7.5M$5.9M
Consignment Sales And Other Revenue$324.7K$321.0K$4.2K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue88¢$17.9M
  • Selling, general and admin11¢$2.2M
  • Interest0¢$97.7K
  • Income tax0¢$63.2K

Out of $20.3M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending12¢$69.9K
  • Kept or used elsewhere88¢$499.3K

Out of $569.2K of cash from operations.4

Financial statements

Revenue4$20.3M in 2025+62% since 2023
0$10.0M$20.0M$30.0M2023: $12.6M$12.6M20232024: $16.7M$16.7M2024+33%2025: $20.3M$20.3M2025+22%
Gross profit4$2.4M in 2025−12% since 2023
0$1.0M$2.0M$3.0M$4.0M2023: $2.7M$2.7M20232024: $3.6M$3.6M2024+30%2025: $2.4M$2.4M2025−32%
Operating income4-$2.3M in 2025+28% since 2023
-$3.0M-$2.0M-$1.0M02023: -$1.8M-$1.8M20232024: -$2.0M-$2.0M2024+9%2025: -$2.3M-$2.3M2025+17%
Net income4-$27.1K in 2025
-$500.0K0$500.0K$1.0M$1.5M2023: $998.2K$998.2K20232024: $1.3M$1.3M2024+33%2025: -$27.1K-$27.1K2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2026-03-312025-03-312024-03-31
Revenues$13.4M$20.3M$16.7M
Cost of revenues-$12.0M-$17.9M-$13.1M
Gross profit$1.4M$2.4M$3.6M
Other income$5.3K$1.5K$4.0K
Selling, general and administrative expenses-$2.4M-$2.2M-$1.9M
Other gains (losses), net$8.5K-$68.7K-$65.0K
Total operating expenses-$2.4M-$2.3M-$2.0M
Operating (loss)/profit-$994.9K$132.0K$1.6M
Financial income$454$1.7K$474
Finance costs-$133.8K-$97.7K-$82.8K
Finance costs, net-$133.4K-$95.9K-$82.3K
(Loss)/profit before income taxes-$1.1M$36.1K$1.5M
Income tax expense-$7.7K-$63.2K-$196.3K
Net (loss)/profit for the year-$1.1M-$27.1K$1.3M
(Loss)/profit attributable to owners of the Company-$1.1M-$27.1K$1.3M
Foreign currency translation adjustments-$20.7K$15.7K-$516
Comprehensive (loss)/income attributable to the Companys shareholders-$1.2M-$11.4K$1.3M
Basic (in Dollars per share)-$0.07-$0.00$0.18
Diluted (in Dollars per share)-$0.07-$0.00$0.18
Basic (in Shares)16.3M shares10.2M shares7.4M shares
Diluted (in Shares)16.3M shares10.2M shares7.4M shares

Compare Cellyan Biotechnology Co., Ltd with another company

Corporate structure

Cellyan Biotechnology Co., Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cellyan Biotechnology Co., Ltd

  • Cellyan Biotechnology Co., Ltd E9

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cellyan Biotechnology Co., Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$111.2K4 Mar 31, 2025$103.2K4 Mar 31, 2024+7.8%
Operating-lease assets (leased space)$482.5K4 Mar 31, 2025$730.5K4 Mar 31, 2024−33.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$748.7K4 Mar 31, 2025$619.6K4 Mar 31, 2024+20.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$560.0K4 Mar 31, 2025$933.3K4 Mar 31, 2024−40.0%

Leadership

Who has led Cellyan Biotechnology Co., Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Chenyu Andy Liang2026–now
Board members and other officers (6)

Former names

  • Hong Kong Pharma Digital Technology Holdings LtdMar 29, 2024 to Dec 17, 20252

Timeline

  1. Jun 8, 2026New chief executive Chenyu Andy Liang becomes CEO6

Filings

66 filings to the SEC since October 2021: 2 annual reports, 7 insider forms, 4 large holders, 53 other. The latest 20:

  1. Sep 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Sep 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Sep 10, 20266-K CURRENT REPORT EDGAR
  4. Aug 13, 2026S-8 REGISTRATION STATEMENT EDGAR
  5. Aug 7, 202620-F ANNUAL REPORT EDGAR
  6. Jul 31, 2026NT 20-F NOTIFICATION OF LATE FILING EDGAR
  7. Jul 16, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  8. Jun 24, 2026EFFECT EDGAR
  9. Jun 12, 2026F-3 REGISTRATION STATEMENT EDGAR
  10. Jun 12, 20263 EDGAR
  11. Jun 10, 20263 EDGAR
  12. Jun 9, 20263 EDGAR
  13. Jun 8, 20263 OWNERSHIP DOCUMENT EDGAR
  14. Jun 8, 20263 OWNERSHIP DOCUMENT EDGAR
  15. Jun 8, 20263 OWNERSHIP DOCUMENT EDGAR
  16. Jun 8, 20263 OWNERSHIP DOCUMENT EDGAR
  17. Apr 8, 2026EFFECT EDGAR
  18. Apr 6, 2026CORRESP EDGAR
  19. Apr 2, 2026UPLOAD EDGAR
  20. Mar 27, 2026F-1 REGISTRATION STATEMENT EDGAR

The 66 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Cellyan Biotechnology Co., Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCellyan Biotechnology Co., Ltd1
  • CIK0002007702
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inE93
  • Fiscal year endsMarch 311
  • Industry code (SIC)5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business addressRoom B1, 5/F. Well Town Ind. Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong1
  • Phone(852) 261892891
  • Shares outstanding16,349,986 shares as of Mar 31, 20263
  • AuditorONESTOP ASSURANCE PAC, Singapore PCAOB ID 6732; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 29, 20241
  • Filings66 in all: 6-K (15), 3 (7), UPLOAD (7), CORRESP (5), DRS/A (5), DRSLTR (4), EFFECT (3), F-1/A (3)1
    All 20 form types

    SCHEDULE 13G (3), 20-F (2), F-1 (2), NT 20-F (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-3 (1), FWP (1), S-8 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Aug 7, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary Shares, par value $0.001 per shareHKPDThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Aug 7, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15